CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Similar documents
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

New Guidelines in Dyslipidemia Management

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

Which CVS risk reduction strategy fits better to carotid US findings?

EuroPRevent Risk assessment models: what is to come? Risk Assessment Models: Applications in Clinical Practice

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Identification of subjects at high risk for cardiovascular disease

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Review of guidelines for management of dyslipidemia in diabetic patients

New Guidelines in Dyslipidemia Management

CVD risk assessment using risk scores in primary and secondary prevention

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Know Your Number Aggregate Report Single Analysis Compared to National Averages

CVD Prevention, Who to Consider

The Metabolic Syndrome: Is It A Valid Concept? YES

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

MOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

No relevant financial relationships

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN


Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Placebo-Controlled Statin Trials

Supplementary Online Content

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

No relevant financial relationships

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Cardiovascular Risk Assessment and Management Making a Difference

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

CARDIOMETABOLIC SYNDROME

How would you manage Ms. Gold

Latest Guidelines for Lipid Management

The Diabetes Link to Heart Disease

Landmesser U et al. Eur Heart J 2017; /eurheartj/ehx549

Beyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital

5/28/2010. Pre Test Question

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

Review current guideline recommendations for lipid-lowering therapy

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Controversies in Preventative Cardiology

40% minimum reduction from

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Unraveling the concealed and calculated cardiovascular risks in diabetes

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

2013 Lipid Guidelines Practical Approach. Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Cardiovascular Risk Assessment: A Systematic Review of Guidelines.

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Carotid Ddisease, Carotid IMT and Risk of Stroke

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

The Art of Cardiovascular Risk Assessment

Practical challenges in CV risk management: When to start intervening in CVD?

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

What s new in cardiovascular disease risk assessment and management for primary care clinicians

Diabetes Mellitus: A Cardiovascular Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Eyes on Korean Data: Lipid Management in Korean DM Patients

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY

Blood Pressure LIMBO How Low To Go?

Cardiovascular risk factor appraisal art or science?

ASSeSSing the risk of fatal cardiovascular disease

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

How to Reduce Residual Risk in Primary Prevention

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

The target blood pressure in patients with diabetes is <130 mm Hg

Lessons from Recent Atherosclerosis Trials

Statistical Fact Sheet Populations

Prevention of Cardiovasular Diseases

CT Calcium Score and Statins in Primary CV Prevention. Dr Selwyn Wong

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

Young high risk patients the role of statins Dr. Mohamed Jeilan

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

How to Reduce CVD Complications in Diabetes?

DYSLIPIDEMIA RECOMMENDATIONS

The Latest Generation of Clinical

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Case Study: Chris Arden. Peripheral Arterial Disease

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Transcription:

CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic

What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This is called an absolute risk Refers to a specific time period (0 years)

Relative Risk and Lifetime Risk Relative risk (RR) is a ratio of risks e.g. % risk in hypertensives, % risk in normotensives RR = 0. / 0.0 = hypertensives have times the risk of normotensives Lifetime risk is the absolute risk of a person for an event during his/her whole remaining life From an individual point of view it is probably the most accurate expression of risk and of intervention benefits

Q: How many risk factors for cardiovascular disease have been described?. 00. 00. 500. > 000 66% 5% % %....

Risk Factors for Cardiovascular Disease Modifiable Smoking Dyslipidaemia raised LDL-C low HDL-C raised triglycerides Raised blood pressure Diabetes mellitus Obesity Dietary factors Thrombogenic factors Lack of exercise Excess alcohol consumption Non-modifiable Personal history of CHD Family history of CHD Age Gender and there are many others ( 000 RFs identified) Adapted from: Pyörälä K et al. Eur Heart J 99;5:00.

Global (Total) Risk Many patients have MULTIPLE CV risk factors OF ALL HYPERTENSIVES 65% have dyslipidaemia 6% have T diabetes 5% are obese/overweight OF ALL DYSLIPIDAEMICS 8% have HTN % have T diabetes 5% are obese/overweight OF ALL T DIABETICS 60% have HTN 60% have dyslipidaemia 90% are obese/overweight Modified after Erhardt LR. Berlin CV Forum, April 008

Global (Total) Risk Multiplicative risk:.9x.x.9x.=.6

When do I assess CVD risk? If the patient asks for it If during a consultation: The person is a middle-aged smoker There is obesity, especially abdominal One or more risk factors such as elevated BP, lipids, or glucose are present or known There is a family history of premature CVD or of risk factors There are symptoms suggestive of CVD Perk J et al. Joint ESC guidelines 0. Eur Heart J 0)

How do I quickly assess CVD risk? HIGH CVD RISK Known CVD TDM or TDM+microalbuminuria Very high levels of individual risk factors Chronic kidney disease (CKD) SCORE chart all others SCORE risk 5% high risk SCORE risk < 5% low to moderate risk Perk J et al. Joint ESC guidelines 0. Eur Heart J 0)

What do these people have in common? years FH Heterozygote TC,8, LDL 9, mmol/l 59 years TDM, HT, DLP TC 6,, LDL,6 mmol/l 66 years CKD, HT, DLP TC 5,, LDL,6 mmol/l. High CVD risk. Need of intensive risk factor modification. Need to achieve treatment goals

How do I quickly assess CVD risk? HIGH CVD RISK Known CVD TDM or TDM+microalbuminuria Very high levels of individual risk factors Chronic kidney disease (CKD) SCORE chart all others SCORE risk 5% high risk SCORE risk < 5% low to moderate risk Perk J et al. Joint ESC guidelines 0. Eur Heart J 0)

Q: How do you estimate CVD risk in your patients?. Using Heart SCORE. Using Framingham point score. Using Reynolds algorythm. Using my best clinical judgement 68% 6% 0% 6%....

Risk Assessment in Everyday Practice 5 years old male Family history: His father died of a heart attack at age 8 Grade hypertensive, sitting BP = 50/90 mm Hg Smoker 0 cigarettes/day for 0 years BMI = 7 kg/m Dyslipidemic: total cholesterol = 60 mg/dl (6.7 mmol/l) HDL-C = 5 mg/dl (. mmol/l) LDL-C = 5 mg/dl (.9 mmol/l) TG = 5 mg/dl (. mmol/l)

Global Risk Assessment Tools in Clinical Practice Several algorythms and charts Framingham UKPDS Risk Engine for TDM patients SCORE charts Heart-SCORE PROCAM Reynolds risk charts NZ Chart Pocock Risk Score

ATP III Framingham Risk Scoring Assessing CHD MM Risk in Men ATP III. JAMA 00;85:86-97

SCORE: Systematic COronary Risk Used since 00 Estimation Based on data from European cohort studies Includes 05 78 patients/79 cardiovascular deaths between years 970-988 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, ESC, 007

www.heartscore.org

Systolic blood pressure (mm Hg) Nonsmoking F Smoking Nonsmoking M Smoking 7 8 9 0 5 7 9 6 9 6 6 0 5 7 5 5 6 7 8 5 6 9 6 0 6 7 8 9 65 9 6 5 6 8 9 8 5 9 5 7 0 5 5 5 6 7 5 6 7 9 9 0 7 5 6 7 8 9 0 9 5 8 8 8 5 5 6 7 8 9 5 5 6 60 6 7 9 0 5 6 7 9 8 7 0 0 7 5 6 6 7 8 0 5 5 6 7 6 7 8 0 6 9 5 55 5 6 7 8 5 6 8 5 9 6 6 8 9 5 6 8 5 6 7 7 8 0 < 50 5 5 6 7 8 0 5 6 7 < < 5 < < < < < < < < < < < < < < < < < < 0 < < < < < < < < < < < < < < < < < < < < < < < 5 6 7 8 5 6 7 8 Age 5 6 7 8 5 6 7 8 Total cholesterol (mmol/l) Total cholesterol (mmol/l)

Systolic blood pressure (mm Hg) Nonsmoking F Smoking Nonsmoking M Smoking 7 8 9 0 5 7 9 6 9 6 6 0 5 7 5 5 6 7 8 5 6 5 6 7 5 9 6 5 8 5 0 6 GENDER 65 AGE BLOOD PRESSURE (untreated) 7 8 9 5 5 6 7 9 0 CHOLESTEROL (untreated) 6 7 8 9 SMOKING 5 5 6 60 9 5 6 6 8 9 9 6 5 6 7 9 5 8 7 9 0 5 6 7 9 8 9 8 8 5 9 5 7 0 0 7 8 7 0 0 7 5 6 6 7 8 0 5 5 6 7 6 7 8 0 6 9 5 5 6 7 8 55 5 6 0 YEAR RISK OF FIRST FATAL CV EVENT >5% RISK IS CONSIDERED AS INCREASED RISK 5 6 7 8 5 7 9 6 6 8 9 5 6 8 8 0 < 50 5 5 6 7 8 0 5 6 7 < < 5 < < < < < < < < < < < < < < < < < < 0 < < < < < < < < < < < < < < < < < < < < < < < 5 6 7 8 5 6 7 8 Age 5 6 7 8 5 6 7 8 Total cholesterol (mmol/l) Total cholesterol (mmol/l)

Risk Assessment in Everyday Practice 5 years old male Family history: His father died of a heart attack at age 8 Grade hypertensive, sitting BP = 50/90 mm Hg Smoker 0 cigarettes/day for 0 years BMI = 7 kg/m Dyslipidemic: total cholesterol = 60 mg/dl (6.7 mmol/l) HDL-C = 5 mg/dl (. mmol/l) LDL-C = 5 mg/dl (.9 mmol/l) TG = 5 mg/dl (. mmol/l)

Systolic blood pressure (mm Hg) Nonsmoking F Smoking Nonsmoking M Smoking 7 8 9 0 5 7 9 6 9 6 6 0 5 7 5 5 6 7 8 5 6 9 6 0 6 7 8 9 65 9 6 5 6 8 9 8 5 9 5 7 0 5 5 5 6 7 5 6 7 9 9 0 7 5 6 7 8 9 0 9 5 8 8 8 5 5 6 7 8 9 5 5 6 60 6 7 9 0 5 6 7 9 8 7 0 0 7 5 6 6 7 8 0 5 5 6 7 6 7 8 0 6 9 5 55 5 6 7 8 5 6 8 5 9 6 6 8 9 5 6 8 5 6 7 7 8 0 < 50 5 5 6 7 8 0 5 6 7 < < 5 < < < < < < < < < < < < < < < < < < 0 < < < < < < < < < < < < < < < < < < < < < < < 5 6 7 8 5 6 7 8 Age 5 6 7 8 5 6 7 8 Total cholesterol (mmol/l) Total cholesterol (mmol/l)

High Relative CVD Risk ESC 007 guidelines on cardiovascular disease prevention proposed a relative risk chart for young people with high levels of risk factors & low absolute risk.

Risk Maybe Higher obese patients (central obesity) family history of premature CVD socially deprived diabetes- risk maybe 5 fold higher in women fold higher in man low HDL cholesterol or high triglycerides asymptomatic patients with evidence of preclinical atherosclerosis (reduced ankle-brachial index, carotid ultrasonography or CT scanning) Perk J et al. Joint ESC guidelines 0. Eur Heart J 0)

Atherosclerosis Imaging in Risk Assessment

Q: Which imaging methods do you use in your practice to improve risk prediction?. Carotid ultrasound. Coronary calcium scoring. CT/MR angiography. I do not use imaging for the purpose of CVD risk stratification 9% 8% % %....

Carotid Ultrasound: INTIMA- MEDIA THICKNESS (CIMT) non-invasive sensitive reproducible technique for identifying and quantifying subclinical vascular disease and for evaluating CV risk

Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography 9 prospective studies, 50 685 asymptomatic patients CIMT significantly associated with risk of MI, stroke, CV death or combination of these events similar or even greater predictive power for carotid plaque and CVD J of ASE, February 008

Carotid Ultrasound: When? in patients with intermediate CVD 0-year risk family history of premature CVD in a first-degree relative < 60 y.o. patients with severe abnormalities in a single risk factor women < 60 y.o. with at least risk factors i.e. if the level of aggressiveness of therapy is uncertain J of ASE, February 008

Carotid Ultrasound: How to Interpret the Results? carotid plaque is defined as >50% wall thickening or CIMT >.5mm that protrudes into the lumen CIMT > or equal to 75th percentile of the patients age, gender and ethnicity are indicative of increased CVD risk J of ASE, February 008

Risk Assessment = Patients Stratification and Treatment Goals Setting Very high risk Documented CVD (angio, stress testing, carotid plaque etc.) T DM or TDM with other RFs and target organ damage /MAU/ Severe CKD (GFR < 0 ml/min/, 7m ) SCORE > 0% High risk Markedly increased levels of individual RFs (e.g. FH) TDM or TDM without RFs and target organ damage Moderate CKD (GFR 0-59ml/min/, 7m ) SCORE 5-0% Moderate risk SCORE -5% (consider other RFs, imaging etc.) Low risk SCORE < % Perk J et al. Joint ESC guidelines 0. Eur Heart J 0)

Target levels of plasma LDL-c according to EAS/ESC 0 Low risk (SCORE < %) + Moderatly increased risk (SCORE -5%) High risk (SCORE 5-0%, marked elevation of single risk factor, DM w/o RFs) Very high risk (SCORE > 0%, CVD+, DM or DM+MAU, CKD) <,8 LDLc (mmol/l) <,0 <,5 EAS/ESC Guidelines on management of DLP, 0 or reduction >50%

CVD Risk Assessment: Initial and Crucial Step in Cardiovascular Prevention The intensity of intervention should be guided by the level of global CV risk, but: Cutoff value for BP: /90 mmhg Cutoff value for TC: 00 mg/dl (?) General principles: The lower the better to targets The sooner the better The safer the better

Thank you